GE Healthcare, the healthcare division of General Electric Company
(NYSE:GE) is working to help physicians potentially improve patient care
throughout the breast cancer journey through one of the most
comprehensive portfolios of technologies in the industry available
today. While at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
(SABCS 2012), taking place in San Antonio from December 5-7, GE
Healthcare will provide attendees with an overview of its innovative
breast cancer solutions for healthcare practitioners. These innovations,
which range from screening to diagnosis, then to staging, treatment
planning and monitoring, recently received Frost & Sullivan's 2012
breast imaging product line strategy award for North America for having
the most comprehensive portfolio and may have a transformational impact
on breast cancer care delivery.
Visitors to the GE Healthcare booth (#225) at SABCS 2012 will also be
able to speak with GE Healthcare experts and executives about its
commitment to innovative patient-focused solutions. GE Healthcare is
also sponsoring a presentation and panel discussion entitled "Enabling
More Confident Decisions for Breast Cancer Treatment” on Thursday,
December 6 at 2:00pm at the Product Theatre in the Exhibit Hall of the
Henry B. Gonzalez Convention Center. Speakers and topics include:
Mammostrat – A Breast Cancer Recurrence Assay – Tamoxifen versus
Exemestane Adjuvant Multicenter (TEAM) Trial Update - John M.S.
Bartlett, MD, Director of Transformative Pathology at Ontario
Institute of Cancer Research, Toronto, Ontario, Canada
Discordance in HER2 Testing in Metastatic Breast Cancer – VIRGO Trial
Update - Edith Perez, MD, Deputy Director at Large, Mayo Clinic Cancer
New Updates and Advances in Ductal Carcinoma In Situ (DCIS) - Craig
Allred, MD, Professor, Department of Pathology, Washington University
School of Medicine
Additionally, results from three GE Healthcare-sponsored studies will be
presented at SABCS 2012:
Presentation P2-10-04 -The Mammostrat Test is an Effective Tool to
Stratify Patient Samples Previously Characterized as Intermediate by
the Oncotype Dx Test – Thursday, December 6, 7:00 – 9:00am, Hall A-B
Presentation P3-05-05 - HER2 Expression and Gene copy analysis by
Immunofluorescence and Fluorescence in situ Hybridization, on a Single
formalin-fixed paraffin-embedded tissue section – Thursday, December
6, 5:00-7:00pm, Hall A-B
Presentation P3-05-06 - Automated Analysis of Her2 FISH Using Combined
Immunofluorescence and FISH Signals – Thursday, December 6,
5:00-7:00pm, Hall A-B
"With a disease as complex and multi-faceted as breast cancer,
innovations need to be equally multi-faceted and even more integrated in
their scope, and GE Healthcare is fully committed to developing
solutions that enable physicians to improve the quality of care provided
to the patients they treat,” said Carrie Eglinton-Manner, CEO, Clarient
Diagnostic Services, a GE Healthcare company. "The studies presented at
SABCS in addition to the information being shared at the product theater
are further demonstration of that commitment.”
A commitment to cancer
In November, GE Healthcare acquired U-Systems, Inc., a manufacturer of
ultrasound products specifically designed for breast applications and
its somo•v® Automated Breast Ultrasound (ABUS). The
somo•v® Automated Breast Ultrasound (ABUS) is the first &
only ultrasound product with FDA approval for screening of breast cancer
as an adjunct to mammography. The addition of this technology is a
reflection of GE’s healthymagination commitment through its global
impact on women’s health and ability to contribute to saving lives.
With the acquisition, GE Healthcare is uniquely positioned to offer U.S.
healthcare providers and their patients the most comprehensive portfolio
of breast care innovations on the market. In addition to digital
mammography and breast magnetic resonance, GE can now offer breast
screening ultrasound ABUS technology to our customers to help in early
detection - which provides for more treatment options.
In addition to its products and services, which demonstrate GE
Healthcare’s commitment to innovative, patient-focused solutions, GE
Healthcare recently announced the launch of ‘Give a Little Beat’, a
musical initiative and a first in the healthcare industry, to connect
people in the fight against breast cancer through the power of music and
social media. By visiting www.givealittlebeat.com,
users will be able to share and listen to songs from the online GE
Healthcare’s Jukebox, powered by Spotify,
the leading digital music service, in support of breast cancer patients
and to raise awareness about the disease. People can participate by
or the ‘Give a Little Beat’ Facebook
App. Songs will be also shared through Twitter, and other social
media platforms, with the #BCMBeats hashtag.
This ongoing initiative supplements the recent campaign announced by GE
Healthcare to mobilize thousands of GE employees to form 'Human
Ribbons' and visually demonstrate the global fight against the
disease during Breast Cancer Awareness Month. It also reinforces the
messages posted on GE’s Breast
Cancer Mosaic, a dedicated site created to share stories from breast
cancer survivors, family members and healthcare professionals to
increase awareness around the disease and to inspire those who are going
through a difficult time.
About GE’s healthymagination Initiative
Launched in May 2009, GE’s healthymagination is a $6 billion global
commitment to provide better health for more people by improving
quality, access and affordability. GE has committed that by 2015 it will:
Invest $6 billion in research and development and financing to launch
at least 100 innovations that will help deliver better care to more
people at lower cost.
Reach 100 million more people every year with services and
technologies essential for health.
Partner with GE employees and their families around the world to help
them live and work in the healthiest way possible, decrease
health-related absences, and strive to limit the growing cost of
More information is available at www.healthymagination.com.
About Clarient Diagnostic Services, Inc.
Clarient Diagnostic Services, Inc. - a GE Healthcare Company - is a
leading provider of comprehensive, cancer–diagnostic laboratory
services. With its advanced technologies, Clarient is able to provide
pathologists and oncologists with more accurate and detailed information
to better characterize and assess cancer, which can lead to more
accurate diagnoses and more effective treatment. In addition, Clarient’s
services are finding more efficient ways to reduce the cost as well as
accelerating the drug development process to identify and develop
treating pharmaceuticals that can result in better outcomes for patients.
From its state-of-the-art diagnostic laboratory to its Internet-based
PATHSiTE®, Clarient delivers advanced oncology diagnostic
services to pathologists, oncologists, hospitals and biopharmaceutical
companies throughout the U.S. Clarient also is developing proprietary
companion diagnostic tests for therapeutics in breast, prostate, lung
and colon cancers, as well as leukemia/lymphoma.
Clarient is improving the lives of those affected by cancer by bringing
clarity to a complex disease.
For more information visit www.clarientinc.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services that are shaping a new age of patient care. Our broad expertise
in medical imaging and information technologies, medical diagnostics,
patient monitoring systems, drug discovery, biopharmaceutical
manufacturing technologies, performance improvement and performance
solutions services help our customers to deliver better care to more
people around the world at a lower cost. In addition, we partner with
healthcare leaders, striving to leverage the global policy change
necessary to implement a successful shift to sustainable healthcare
Our "healthymagination" vision for the future invites the world to join
us on our journey as we continuously develop innovations focused on
reducing costs, increasing access and improving quality and efficiency
around the world. Headquartered in the United Kingdom, GE Healthcare is
a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE
Healthcare employs more than 46,000 people committed to serving
healthcare professionals and their patients in more than 100 countries.
For more information about GE Healthcare, visit our web site at www.gehealthcare.com.
For our latest news, please visit http://newsroom.gehealthcare.com